Evidence map›Paper›PMID 41591829›Full record

ArticleJCI insight2026

Schlafen 5 is an intracellular immune checkpoint and controls IFN responses in pancreatic ductal adenocarcinoma.

Mariafausta Fischietti, Markella Zannikou, Elspeth M Beauchamp, Diana Saleiro, Aneta H Baran, Briana N Hryhorysak, Jamie N Guillen Magaña, Emely Lopez Fajardo, Gavin T Blyth, Brandyn A Castro and 7 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mariafausta FischiettiRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Markella ZannikouRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Elspeth M BeauchampRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Diana SaleiroRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Aneta H BaranRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Briana N HryhorysakRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Jamie N Guillen MagañaRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Emely Lopez FajardoRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Gavin T BlythRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Brandyn A CastroDepartment of Neurological Surgery.
Jason M MiskaRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Catalina Lee-ChangRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Priyam PatelRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Elizabeth T BartomRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Masha KocherginskyRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Frank EckerdtRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Leonidas C PlataniasRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
CARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4M
Signal Transduction of Type I Interferons in Malignant CellsR01CA077816 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 1998 to 2024
$6.6M
Development of B-cell-based vaccine for GlioblastomaR37CA258426 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Catalina Lee Chang · 2021 to 2026
$2.2M
Bioinformatics Analysis of Next Generation Sequencing Data from Cancer CellsR50CA221848 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Elizabeth Thomas Bartom · 2017 to 2026
$1.8M
SLFN5: A Novel Therapeutic Target for GlioblastomaR01NS113352 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2019 to 2023
$1.7M
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA077816NCI NIH HHS R37 CA258426NCI NIH HHS R50 CA221848NCI NIH HHS T32 CA009560NINDS NIH HHS R01 NS113352
6 · The paper itself

Abstract

We provide evidence that human and murine Schlafen 5 (SLFN5) proteins are modulators of type I IFN responses and the immune response in pancreatic ductal adenocarcinoma (PDAC). Blocking expression of Slfn5 in PDAC enhanced IFN responses, suppressed tumor growth, and prolonged survival in immunocompetent mice. Notably, immunophenotypic analysis revealed a reduction in tumor-associated macrophages alongside an increase in tumor-infiltrating effector cells in tumors over time. These findings suggest SLFN5 acts as an intracellular immune checkpoint and identify it as a unique therapeutic target for the development of therapies for PDAC and possibly other malignancies.

Indexed as

Carcinoma, Pancreatic DuctalInterferon Type IPancreatic NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceTumor-Associated MacrophagesInterferon Type ICancerCell biologyCytokinesOncology

Identifiers

PMID41591829
PMCPMC13041689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.